Septodont North America Introduces Flavalta™ — The First and Only Lidocaine with Flavoring Agents

LANCASTER, Pa. — Septodont North America, a global leader in dental anesthetics, is proud to announce the launch of Flavalta™ lidocaine hydrochloride 2% with epinephrine 1:100,000, the first and only lidocaine formulation with flavoring agents. Representing Septodont’s most significant dental local anesthetic formulation innovation in more than 25 years, Flavalta™ builds on the trusted clinical performance of lidocaine with a formulation that incorporates flavoring agents.

Since its introduction in dentistry in 1948, lidocaine has remained the gold standard for local anesthesia. Flavalta™ builds on that legacy by incorporating sodium saccharin, a non-nutritive sweetener, and L-serine, a naturally occurring amino acid recognized for its flavor-enhancing properties. Both ingredients have been approved by the U.S. Food and Drug Administration for safe use as sweetening and flavor-enhancing agents in food, beverages, and pharmaceutical products.

Enhanced Patient Experience. Proven Performance.

Patient feedback and market research have highlighted taste as an important consideration with dental anesthetics and an opportunity to enhance the overall experience. “There is nothing better than to take a concern of our dentist customers & their patients and give them a solution,” said Paul Mondock, President North America & Global Sales Services. ” By adding flavoring agents while maintaining the reliability and clinical performance practitioners depend on, Flavalta represents the next evolution of local anesthesia.”

Flavalta™ combines trusted anesthetic efficacy with innovative flavoring agent technology and offers:

• Fast, reliable onset

• Infiltration anesthesia: average onset in less than 2 minutes
• Nerve block anesthesia: average onset in 2–4 minutes

• Clinically effective duration

• Approximately 60 minutes for infiltration procedures
• Approximately 90 minutes of pulpal anesthesia for nerve block procedures

• Methylparaben-free formulation

• Designed to reduce the risk of allergic reactions in sensitive patients

• Latex-free components

• Contains no natural rubber latex, supporting safer use across a wider patient population

• Terminally sterilized cartridges

• Providing a high level of sterility and safety for every injection

Availability

Flavalta™ lidocaine hydrochloride 2% with epinephrine 1:100,000 is available through authorized dental distributors across the United States. Flavalta should be used in accordance with the approved prescribing information. Please see Full Prescribing Information at septodontusa.com/product/pain-management-flavalta.

About Septodont North America

Septodont North America is part of the Septodont Group, a global leader in dental pain management and dental pharmaceuticals with more than 90 years of experience developing innovative products for dental professionals. From the creators of Septocaine®, Septodont serves practitioners across the United States and Canada with a comprehensive portfolio of solutions in local anesthesia, restorative dentistry, endodontics, and infection control. Septodont products are used by dental professionals in more than 150 countries worldwide, with the company producing approximately 500 million dental anesthetic cartridges annually.

Septodont North America 205 Granite Run Drive, Suite 150 Lancaster, PA 17601 www.septodontusa.com